Citius Pharmaceuticals (CTXR) EBT (2010 - 2026)

Citius Pharmaceuticals (CTXR) has reported EBT for 17 consecutive years, with -$12.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT fell 34.53% year-over-year to -$12.0 million; the trailing twelve-month figure through Jun 2026 stood at -$58.0 million (down 40.94% YoY), and the FY2025 full-year result was -$38.7 million, changed 0.43% from the prior year.
• EBT rose to -$12.0 million in Q2 2026 per CTXR's latest filing, from -$28.3 million in the prior quarter.
• Across five years, EBT topped out at -$3.4 million in Q4 2022 and bottomed at -$28.3 million in Q1 2026.
• Historically, EBT has averaged -$10.2 million across 5 years, with a median of -$9.1 million in 2023.
• The sharpest annual moves came in 2022 and 2023: EBT jumped 62.61% in 2022, then slumped 163.42% in 2023.
• Over 5 years, EBT stood at -$3.4 million in 2022, then plunged by 163.42% to -$9.1 million in 2023, then slipped by 10.23% to -$10.0 million in 2024, then rose by 8.86% to -$9.1 million in 2025, then sank by 31.73% to -$12.0 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$12.0 million, -$28.3 million, and -$9.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.